Immunotherapy of Human Tumors with Antibodies Against EGF Receptor
Author Information
Author(s): H. Modjtahedi, S. Eccles, G. Box, J. Styles, C. Dean
Primary Institution: Institute of Cancer Research
Hypothesis
Can rat monoclonal antibodies targeting the EGF receptor effectively treat human tumor xenografts in athymic mice?
Conclusion
The study found that certain rat monoclonal antibodies can induce complete regression of human tumor xenografts in mice.
Supporting Evidence
- ICR16 and ICR62 antibodies induced complete regression of HN5 tumors when treatment started at tumor implantation.
- ICR62 was particularly effective, inducing complete remission of MDA-MB 468 tumors with a low total dose.
- ICR62 delayed the growth of SKOV3 tumors despite being ineffective in vitro.
Takeaway
Scientists tested new medicines made from rat antibodies to help mice with human tumors, and some worked really well to make the tumors go away.
Methodology
Athymic mice with human tumor xenografts were treated with rat monoclonal antibodies to assess their effectiveness in tumor regression.
Limitations
The study primarily involved animal models, which may not fully represent human responses.
Participant Demographics
Athymic mice bearing human tumor xenografts.
Want to read the original?
Access the complete publication on the publisher's website